-

Johnson & Johnson to Participate in the 2023 Wells Fargo Securities Healthcare Conference

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will participate in the 2023 Wells Fargo Securities Healthcare Conference at the Encore Boston Harbor in Everett, MA on Thursday, September 7th. Ashley McEvoy, EVP, Worldwide Chairman, MedTech along with executives from Abiomed will represent the Company in a session scheduled at 10:15 a.m. (Eastern Time).

This conference call will be available to investors and other interested parties by visiting the Johnson & Johnson website at www.investor.jnj.com.

A webcast and podcast replay will be available approximately 48 hours after the live webcast.

Contacts

Investor Contact:
RA-JJCUS-InvestorRel@ITS.JNJ.com

Media Contact:
media-relations@its.jnj.com

Industry:

Johnson & Johnson

NYSE:JNJ
Release Versions
English

Contacts

Investor Contact:
RA-JJCUS-InvestorRel@ITS.JNJ.com

Media Contact:
media-relations@its.jnj.com

More News From Johnson & Johnson

Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2025

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the third quarter of 2025 of $1.30 per share on the company’s common stock. The dividend is payable on September 9, 2025 to shareholders of record at the close of business on August 26, 2025. The ex-dividend date is August 26, 2025. About Johnson & Johnson At Johnson & Johnson, we believe health is everything. Our strength in healthcare inn...

Johnson & Johnson Reports Q2 2025 Results; Raises 2025 Outlook

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter 2025. “Today’s strong results reflect the depth and strength of Johnson & Johnson’s uniquely diversified business operating across both MedTech and Innovative Medicine,” said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. “Our portfolio and pipeline position us for elevated growth in the second half of the year, with game-changing approvals and subm...

Johnson & Johnson Elects Daniel Pinto, President, JPMorganChase to its Board of Directors

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) announced today that Daniel Pinto, President, JPMorganChase, has been elected to its Board of Directors. “We are thrilled to have Daniel join Johnson & Johnson’s Board of Directors,” said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. “He is an exceptional leader with deep financial expertise and understanding of global capital markets. Daniel’s unique perspective and wealth of experience wi...
Back to Newsroom